MAIA
What one share of MAIA Biotechnology holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 ‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
MAIA Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.61 |
|---|---|
| Cash and investments | $0.00 |
| Book value | $0.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$2.37 | — | −$0.78 | — | $1.21 |
| 2022 | $0.00 | −$1.75 | — | −$1.30 | — | $0.78 |
| 2023 | $0.00 | −$1.49 | — | −$0.99 | — | $0.03 |
| 2024 | $0.00 | −$1.05 | — | −$0.71 | — | $0.14 |
| 2025 | — | −$0.70 | — | −$0.59 | — | $0.06 |